KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (IS) (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Depreciation & Amortization (IS) for 4 consecutive years, with $7.5 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation & Amortization (IS) fell 45.46% year-over-year to $7.5 million, compared with a TTM value of $24.4 million through Dec 2023, down 12.38%, and an annual FY2024 reading of $90.8 million, up 272.41% over the prior year.
  • Depreciation & Amortization (IS) was $7.5 million for Q4 2023 at AbCellera Biologics, up from $5.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (IS) topped out at $13.8 million in Q4 2022 and bottomed at $41000.0 in Q3 2020.
  • Average Depreciation & Amortization (IS) over 4 years is $4.5 million, with a median of $4.0 million recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (IS) skyrocketed 8841.46% in 2021, then crashed 45.46% in 2023.
  • Year by year, Depreciation & Amortization (IS) stood at $3.3 million in 2020, then increased by 18.93% to $4.0 million in 2021, then surged by 249.09% to $13.8 million in 2022, then crashed by 45.46% to $7.5 million in 2023.
  • Business Quant data shows Depreciation & Amortization (IS) for ABCL at $7.5 million in Q4 2023, $5.7 million in Q3 2023, and $5.6 million in Q2 2023.